title: Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.
abstract: The landscape for the second- and third-line treatment of advanced non-small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following progression on platinum-based first-line chemotherapy. However, there remains a role for cytotoxic chemotherapy and pemetrexed and docetaxel (with or without ramucirumab) are approved for single-agent use in the second-line setting. With the discovery of new genetic alterations and the development of novel targeted drugs, the treatment of advanced non-small cell lung cancer following progression on first-line therapy continues to become more complicated as new treatment algorithms evolve.
authors.affiliation: Department of Hematology/Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA. Electronic address: gdurm@iu.edu.
authors.forename: Greg
authors.initials: G
authors.lastname: Durm
authors.affiliation: Department of Hematology/Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA.
authors.forename: Nasser
authors.initials: N
authors.lastname: Hanna
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D000077143:Docetaxel; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D000068437:Pemetrexed / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077143:Docetaxel; D066246:ErbB Receptors; D000069347:Erlotinib Hydrochloride; D000068437:Pemetrexed; D043823:Taxoids; D000096662:Ramucirumab; C512478:EGFR protein, human
keywords: Chemotherapy; Docetaxel; Erlotinib; Non–small cell lung cancer; Pemetrexed; Second-line treatment